A Study To Evaluate The Effect of T89(Dantonic®)On P450 Enzymes
NCT ID: NCT01473888
Last Updated: 2012-11-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
24 participants
INTERVENTIONAL
2011-01-31
2012-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The product is also marketed, as a drug, in Russia, South Korea, Mongolia, Singapore, Vietnam, and South Africa. The current study is to determine the anti-angina effect and dose response of T89 in patients with chronic stable angina pectoris in the United States.
T89 consists of Danshen (Radix Salviae Miltiorrhizae, RSM) and Sanqi (Radix Notoginseng, RN) as active constitutes, and using Borneol as transporting enhancer.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
T89
T89(Dantonic)
capsule, 225mg B.I.D.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
T89(Dantonic)
capsule, 225mg B.I.D.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Healthy adult with no active medical problems or significant chronic diseases as determined by the study doctor based on history, physical exam and laboratory evaluations;
* Avoid eating Seville oranges, grapefruits (including grapefruit juice), broccoli, brussels sprouts, charcoal-grilled meats, alcoholic beverages, and caffeine- and theobromine-containing beverages and foods for the duration of the study beginning at the screening visit.
* Females of child bearing potential must be able to maintain adequate birth control during the study; defined as double barrier method or complete abstinence. Females of non-child bearing potential must provide documentation of tubal ligation or hysterectomy.
* Be able to provide written informed consent and comply with requirements of the study;
* Be able to read, speak and understand English
Exclusion Criteria
* Know hypersensitivity or intolerance to any of the probe substrates or the active and/or inactive ingredients in the probe substrates, flumazenil, guaifenesin, or vitamin K;
* A history of illicit drug use or a history of alcohol abuse within 1 year of screening.
* Women who are pregnant, breastfeeding, and/or not using an acceptable form of non-hormonal contraception (double barrier method or abstinence) during the study.
* History of gastrointestinal bleeding or peptic ulcer disease.
* Any condition that may affect drug absorption (e.g., gastrectomy, malabsorption syndromes).
* Had an elevated international normalized ratio (INR) time (INR\> 1.2) at screening or Day-1.
* Had taken any nicotine-containing or nicotine replacement devices within 6 months before the screening visit
* Had taken any prescription drugs during the 3 months before the screening visit
* Had taken any nonprescription drugs (including natural health products, Vitamins, and herbals) during a period of 7 days prior to the screening visit
* Had received an immunization during the 2 weeks prior to the screening visit
* Had known immune deficiency disease or were positive for human immunodeficiency virus, Hepatitis B or Hepatitis C virus.
* Use of any drug known to inhibit or induce hepatic enzymes within 30 days of the first study phase.
* Regular alcohol intake exceeding 1 drink/day (1 drink = 5 ounces of wine or 12 ounces of beer or 1 ounce of hard liquor) within 7 days of screening.
* Treatment with an investigational drug within 30 days or 5 half-lives (whichever is longer) preceding the first dose of study drug.
* Presence of any condition that the investigator feels would interfere with successful completion of the study.
* Genotyping of poor metabolizers for CYP2D6, CYP2C9, and CYP2C19.
18 Years
50 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Tasly Pharmaceuticals, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jason Zhixin GUO, M.D.
Role: STUDY_DIRECTOR
Tasly Pharmaceuticals Co. Ltd.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Comprehensive Clinical Development NW Inc.
Tacoma, Washington, United States
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Related Info
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
T89-02-US
Identifier Type: -
Identifier Source: org_study_id